ArticleBiochemical genetics2026
Downexpression of miR- 17 - 5p and miR- 125a- 5p is Potentially Associated with the Renal Impairment Through STAT- 3 and CD69 in Multiple Myeloma Adult Patients.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Promoter Methylation of HOXA5 and NDRG2 in Multiple Myeloma Patients with Renal Impairment.Biochemical genetics · 2026Article
- Integrated analysis of miR-15a-5p, miR-20a-5p, and miR-33b-3p identifies EGR2-associated biomarkers in multiple myeloma.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) frequently causes renal impairment (RI), and clinical therapy becomes more challenging if renal function deteriorates or renal failure results. Therefore, in order to evaluate their prognostic potential in predicting renal impairment risk in MM patients, we investigated the expression levels of miR- 17 - 5p and miR- 125a- 5p as well as STAT3 and CD69 proteins as probable shared target genes in MM adult patients with and without RI. This study included 60 controls and 120 MM patients. By using RT-qPCR, the expression levels of miR- 17 - 5p and miR- 125a- 5p in the sera of MM patients and controls were evaluated. Also, the expression levels of CD69 and STAT- 3 were examined using ELISA and flowcytometry techniques, respectively. When MM patients were compared to controls and MM patients with RI to MM patients without RI, the expression levels of miR- 17 - 5p and miR- 125a- 5p were reduced, but CD69 and STAT- 3 were elevated. Results obtained from ROC curve showed that they were good prognostic biomarkers could predict renal impairment in MM patients, with AUC 0.754, 0.936, 1 & 0.991; respectively for miR- 17 - 5p, miR- 125a- 5p, STAT- 3 and CD69, 60%, 93.3%, 100% & 96.7% sensitivity and 73.3%, 86.7%, 100% & 90% specificity; respectively for miR- 17 - 5p, miR- 125a- 5p, STAT- 3 and CD69. While for Kaplan-Meier survival, our results indicated that patients with lower expression levels of miR- 17 - 5p and miR- 125a- 5p, but higher STAT- 3 and CD69 concentration, had a poorer prognosis and possessing a shorter OS. The integrated approach reveals miR- 17 - 5p, miR- 125a- 5p, CD69, and STAT- 3 as reliable prognostic biomarkers for predicting renal impairment in MM patients.
Indexed as
Identifiers
40266492What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.